Contributed Abstracts
Hall 1 (Salt Palace Convention Center)
Regulatory T CELLS Specific for Minor Histocompatibility Antigens
Anandaraman Veerapathran, PhD, Moffitt Cancer Center;
Francisca Beato, BS, Moffitt Cancer Center;
Joseph Pidala, MD, MS, Moffitt Cancer Center;
William Janssen, PhD, Moffitt Cancer Center;
Xue-Zhong Yu, MD, H. Lee Moffitt Cancer Center & Research Institute;
Claudio Anasetti, MD, H. Lee Moffitt Cancer Center
A Novel Approach to Manufacture CAR-T Cells for Clinical Applications
Pradip Bajgain, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Roopa Mucharla, MSc, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Usanarat Anurathapan, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Natalia Lapteva, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Ann M Leen, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Helen E Heslop, MD, Baylor College of Medicine, Texas Children's Hospital;
Cliona M. Rooney, PhD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital;
Juan F. Vera, MD, Baylor College of Medicine, Texas Children's Hospital, The Methodist Hospital
Novel Immunodominant CD4+ T Cell Epitopes in the CMV Proteins IE1 and IE2
Peter Braendstrup, MD, Rigshospitalet, Copenhagen University Hospital;
Sune Justesen, Faculty of Health Sciences, University of Copenhagen;
Thomas Østerby, Faculty of Health Sciences, University of Copenhagen;
Bo Kok Mortensen, MD, Rigshospitalet, Copenhagen University Hospital;
Claus Bohn Christiansen, MD, Rigshospitalet, Copenhagen University Hospital;
Michael Rasmussen, Msc, Faculty of Health Sciences, University of Copenhagen;
Lars Lindhardt Vindelov, MD, Rigshospitalet, Copenhagen University Hospital;
Soren Buus, MD, Faculty of Health Sciences, University of Copenhagen;
Anette Stryhn, Ph.d, Faculty of Health Sciences, University of Copenhagen
Capitalizing On Epitope Escape to Avoid T Cell Fratricide without Compromising Targeting of CD56+ Tumors
Denise Crossland, B.S. Biology, B.S. Biochem, MD Anderson Cancer Center UTHSCH;
Sonny Ang, PhD, University of Texas MD Anderson Cancer Center;
Simon Olivares, MS, University of Texas MD Anderson Cancer Center;
Helen Huls, BS, UT MDACC, Houston;
Laurence J.N. Cooper, MD, PhD, UT MDACC
Evaluating Donor Lymphocyte Infusions (DLI) for the Treatment of Falling Chimerism, Minimal Residual Disease and Relapse After Pediatric Hematopoietic Stem Cell Transplantation (HSCT)
Javier Amin El-Bietar, MD, Baylor College of Medicine, Texas Children's Hospital;
Caridad Martinez, MD, Baylor College of Medicine, Texas Children's Hospital;
Catherine M. Bollard, MD, Baylor College of Medicine, Texas Children's Hospital;
Swati Naik, Baylor College of Medicine, Texas Children's Hospital;
Kathryn Leung, MD, Baylor College of Medicine, Texas Children's Hospital;
Stephen Gottschalk, MD, Baylor College of Medicine, Texas Children's Hospital;
Nabil Ahmed, MD, Baylor College of Medicine;
Carl Allen, MD, PhD, Baylor College of Medicine, Texas Children's Hospital;
Helen E Heslop, MD, Baylor College of Medicine, Texas Children's Hospital;
Malcolm K. Brenner, MD, PhD, Baylor College of Medicine, Texas Children's Hospital;
Robert A. Krance, MD, Baylor College of Medicine, Texas Children's Hospital
Towards the Development of a Closed, Nanofiber-Based Culture System for Clinical Expansion of Cord Blood CD34+ Cells
Stephen E Fischer, PhD, Arteriocyte, Inc;
Yukang Zhao, MS, Arteriocyte, Inc;
Anirudhasingh Sodha, MS, Arteriocyte, Inc;
Caitlin Smith, BS, Arteriocyte, Inc;
Yiwei Ma, MS, Arteriocyte, Inc
CD19-Specific T Cells Developed to Persist When Antigen Load Is Low: Implications for Treating Minimal Residual Disease After Hematopoietic Stem-Cell Transplantation
Lenka V. Hurton, University of Texas MD Anderson Cancer Center;
Kirsten Switzer, Ph.D., University of Texas MD Anderson Cancer Center;
Harjeet Singh, Ph.D., University of Texas MD Anderson Cancer Center;
Marie A. Forget, Ph.D., University of Texas MD Anderson Cancer Center;
Tiejuan Mi, University of Texas MD Anderson Cancer Center;
Simon Olivares, MS, University of Texas MD Anderson Cancer Center;
Richard E. Champlin, MD, The University of Texas MD Anderson Cancer Center;
Dean A. Lee, MD, PhD, University of Texas MD Anderson Cancer Center;
Laurence J.N. Cooper, MD, PhD, University of Texas MD Anderson Cancer Center
Multi-Center Phase I Study of Th1/Tc1 Immunotherapy Following Autologous Hematopoietic Progenitor Cell Transplantation in Reccurrent or High Risk Plasma Cell Myeloma
Claude Sportes, NCI;
Kristen Cole, NCI;
David Siegel, MD, PhD, Hackensack University Medical Center;
Scott Rowley, MD, Hackensack University Medical Center;
David Halverson, MD, NCI;
Nancy Hardy, MD,, NCI;
Steven Z. Pavletic, MD, NCI;
Juan Gea-Banacloche, MD, NCI;
Jennifer Mann, NCI;
Amanda Urban, NCI;
Vicki Fellowes, NCI;
Marianna Sabatino, NIH;
David F. Stroncek, MD, National Heart, Lung and Blood Institute NHLBI;
Bruce Levine, PhD, University of Pennsylvania;
Miriam Mossoba, NCI;
Shoba Amarnath, PhD, NCI;
Carl H. June, MD, University of Pennsylvania;
Ronald Gress, MD, NCI;
Daniel Fowler, MD, NCI
![[Visit Client Website]](images/banner.gif)